Genprex (NASDAQ:GNPX) Announces Earnings Results

Genprex (NASDAQ:GNPX) issued its earnings results on Friday. The company reported ($9.40) earnings per share for the quarter, Zacks reports.

Genprex Price Performance

Shares of NASDAQ GNPX traded down $0.55 during mid-day trading on Friday, hitting $4.32. 90,681 shares of the company’s stock traded hands, compared to its average volume of 61,769. Genprex has a 1 year low of $4.00 and a 1 year high of $1,210.00. The company’s 50-day moving average is $9.69 and its two-hundred day moving average is $25.41. The company has a market capitalization of $2.16 million, a P/E ratio of -0.01 and a beta of -0.88.

Institutional Trading of Genprex

A hedge fund recently raised its position in Genprex stock. Susquehanna International Group LLP boosted its position in shares of Genprex (NASDAQ:GNPX) by 11.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 340,056 shares of the company’s stock after buying an additional 35,661 shares during the quarter. Susquehanna International Group LLP owned 27.20% of Genprex worth $58,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 14.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on GNPX shares. Wall Street Zen upgraded shares of Genprex from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Genprex in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Genprex Company Profile

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.